[go: up one dir, main page]

NO996133D0 - Oil-in-water vaccine formulations - Google Patents

Oil-in-water vaccine formulations

Info

Publication number
NO996133D0
NO996133D0 NO996133A NO996133A NO996133D0 NO 996133 D0 NO996133 D0 NO 996133D0 NO 996133 A NO996133 A NO 996133A NO 996133 A NO996133 A NO 996133A NO 996133 D0 NO996133 D0 NO 996133D0
Authority
NO
Norway
Prior art keywords
oil
vaccine formulations
water vaccine
water
formulations
Prior art date
Application number
NO996133A
Other languages
Norwegian (no)
Other versions
NO996133L (en
Inventor
Nathalie Garcon
Patricia Marie Christine Momin
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO996133D0 publication Critical patent/NO996133D0/en
Publication of NO996133L publication Critical patent/NO996133L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO996133A 1997-06-11 1999-12-10 Oil-in-water vaccine formulations NO996133L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711990.3A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine
PCT/EP1998/003479 WO1998056414A1 (en) 1997-06-11 1998-06-03 Oil in water vaccine compositions

Publications (2)

Publication Number Publication Date
NO996133D0 true NO996133D0 (en) 1999-12-10
NO996133L NO996133L (en) 2000-01-26

Family

ID=10813866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996133A NO996133L (en) 1997-06-11 1999-12-10 Oil-in-water vaccine formulations

Country Status (17)

Country Link
EP (1) EP0999852A1 (en)
JP (1) JP2002504106A (en)
KR (1) KR20010013644A (en)
CN (1) CN1260723A (en)
AR (1) AR012959A1 (en)
AU (1) AU728759B2 (en)
BR (1) BR9810614A (en)
CA (1) CA2293444A1 (en)
CO (1) CO4940401A1 (en)
GB (1) GB9711990D0 (en)
HU (1) HUP0004001A3 (en)
IL (1) IL133126A0 (en)
NO (1) NO996133L (en)
PL (1) PL337488A1 (en)
TR (1) TR199903048T2 (en)
WO (1) WO1998056414A1 (en)
ZA (1) ZA984969B (en)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
TR200103018T2 (en) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline Additive compounds containing immunostimulatory oligonucleotide and saponin.
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CZ20013916A3 (en) * 1999-05-13 2002-06-12 American Cyanamid Company Adjuvant compound preparations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001030382A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1282702B1 (en) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
SI2266603T1 (en) 2000-10-18 2012-12-31 Glaxosmithkline Biologicals S.A. Tumour vaccines
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
JP2005504070A (en) * 2001-09-13 2005-02-10 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー Oil-based paclitaxel composition and formulation for chemical embolization and method for producing the same
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
EP1569515A4 (en) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa METHODS OF VACCINATION AGAINST MALARIA
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
DE602005025342D1 (en) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa VACCINE COMPOSITIONS WITH VIRUSOMES AND A SAPONIN ADJUVANS
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1863529A1 (en) 2005-03-23 2007-12-12 GlaxoSmithKline Biologicals S.A. Novel composition
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
HUE051122T2 (en) * 2005-11-04 2021-03-01 Seqirus Uk Ltd Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL3017827T3 (en) 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
KR101541383B1 (en) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. immunogenic composition
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
MX2009000660A (en) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Influenza vaccine.
US9592282B2 (en) 2006-07-18 2017-03-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8137678B2 (en) 2006-11-03 2012-03-20 Intervet Inc. Canine lyme disease vaccine
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa Novel method and compositions
PE20090146A1 (en) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa IMMUNOGENIC COMPOSITION AGAINST THE INFLUENZA VIRUS
US9610339B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
TW200924791A (en) 2007-08-13 2009-06-16 Glaxosmithkline Biolog Sa Vaccines
ES2626634T3 (en) 2007-12-19 2017-07-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
JP5722782B2 (en) 2008-09-26 2015-05-27 ナノバイオ コーポレーション Nanoemulsion therapeutic composition and method of use thereof
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
LT2437753T (en) 2009-06-05 2016-12-12 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
EP3020412B1 (en) 2009-06-16 2017-10-11 The Regents of the University of Michigan An immunogenic composition comprising nanoemulsion inactivated rsv
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (en) * 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and improved methods of making the same
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
SG184188A1 (en) 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
KR20130139953A (en) 2010-09-27 2013-12-23 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccine
MX354752B (en) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Heterologous prime boost vaccination regimen against malaria.
CN103282375B (en) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 peptide scaffold design
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
BR112013017488A2 (en) 2011-01-06 2017-08-01 Bionor Immuno As multimeric and monomeric immunogenic peptides
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013038156A1 (en) 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
LT2850431T (en) 2012-05-16 2018-06-25 Immune Design Corp. Vaccines for hsv-2
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR101819803B1 (en) 2012-10-24 2018-01-17 플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 Platelet targeted treatment
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
KR102039520B1 (en) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN105992770B (en) 2013-11-01 2021-06-25 奥斯陆大学 Variants of albumin and their uses
WO2015070207A2 (en) 2013-11-11 2015-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
CA2929126C (en) 2013-11-13 2020-01-07 University Of Oslo Outer membrane vesicles and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
EA201691028A1 (en) 2013-11-20 2017-01-30 Ла Хойя Инститьют Фор Эллерджи Энд Иммьюнолоджи PAN-IMMUNOGENES POLLENS, METHODS AND APPLICATIONS FOR IMMUNE RESPONSE MODULATION
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial vaccine formulations
WO2015112485A1 (en) 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
KR101696514B1 (en) * 2014-08-18 2017-01-24 서울대학교산학협력단 Temperature Sensitive Mycobacterial strain and its use as vaccine against mycobacterial infection disease
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
UA125378C2 (en) 2016-03-14 2022-03-02 Універшітетет І Осло MODIFIED IMMUNOGLOBULINS WITH CHANGED FcRn BINDING
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
CA3034124A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
KR102673794B1 (en) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 Nanostructured lipid carriers and stable emulsions and their uses
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
US11648304B2 (en) 2017-11-03 2023-05-16 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN112638936A (en) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 Adenovirus polynucleotides and polypeptides
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
CN114340665A (en) 2019-05-25 2022-04-12 传染病研究所 Compositions and methods for spray drying adjuvant vaccine emulsions
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Inst Immunogenic vaccine composition incorporating a saponin
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
AU728759B2 (en) 2001-01-18
AR012959A1 (en) 2000-11-22
NO996133L (en) 2000-01-26
JP2002504106A (en) 2002-02-05
EP0999852A1 (en) 2000-05-17
TR199903048T2 (en) 2000-08-21
GB9711990D0 (en) 1997-08-06
PL337488A1 (en) 2000-08-28
AU8336598A (en) 1998-12-30
HUP0004001A3 (en) 2001-07-30
HUP0004001A2 (en) 2001-03-28
WO1998056414A1 (en) 1998-12-17
BR9810614A (en) 2000-09-12
IL133126A0 (en) 2001-03-19
CA2293444A1 (en) 1998-12-17
CN1260723A (en) 2000-07-19
ZA984969B (en) 1999-12-09
KR20010013644A (en) 2001-02-26
CO4940401A1 (en) 2000-07-24

Similar Documents

Publication Publication Date Title
NO996133D0 (en) Oil-in-water vaccine formulations
NO20003302D0 (en) Vaccine
BR9711853A (en) Vaccines
DE69800383D1 (en) Influenza vaccine
MA24473A1 (en) FORMULATIONS
DK0921796T3 (en) Tetrahydrolipstatin-containing preparations
DE69833739D1 (en) Cosmetic preparation
DK1210113T3 (en) Combined vaccine preparations
ID23299A (en) PHARMACEUTICAL FORMULATIONS
ID25533A (en) 2-METHYL-TIENO-BENZODIAZEPIN FORMULATION
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
NO20006191D0 (en) Vaccine
NO20000231D0 (en) Dolastatin-15 derivatives
ID17860A (en) VACCINE COMPOSITION
ID16781A (en) PHARMACEUTICAL FORMULATIONS
EP0967993A4 (en) ANTI-COCOA VACCINE
NO20005599D0 (en) Vaccine
ATE298576T1 (en) MEDICINAL PREPARATIONS
ITMI941169A0 (en) PHARMACEUTICAL FORMULATIONS
ATE237309T1 (en) MEDICINAL PREPARATIONS
EP1142589A4 (en) MEDICINAL PREPARATIONS
NO991430L (en) Insecticide formulations
NO970852D0 (en) footrest
KR980000493U (en) chair
FI3862U1 (en) Gel-shaped pharmaceutical preparation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application